QIAGEN Expands QIAstat-Dx Portfolio In US With FDA Clearance Of Rise For Rapid Infectious Disease Diagnostics

Benzinga · 09/02/2025 06:18
  • U.S. market entry set to begin for QIAstat-Dx Rise – a version of QIAstat-Dx for syndromic testing that combines unparalleled throughput with the easiest workflow
  • QIAstat-Dx Rise launch can process up to 160 samples per day, initial launch includes Respiratory Panel Plus and Respiratory Panel Mini and additional panels in development
  • Expansion of QIAstat-Dx instrument portfolio in the U.S. builds on the availability of both system options in Europe and other regions of the world